Stay updated on Pralsetinib in RET+ Cancer Clinical Trial
Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page
- Check4 days agoChange DetectedThe update shows recruitment has ended by displaying 'No longer looking for participants,' and adds help/navigation items such as 'How to Read a Study Record,' 'Common Questions,' and 'How to Join a Study,' along with minor label/version changes to 'Intervention/Treatment' and revision tags.SummaryDifference0.2%

- Check11 days agoChange DetectedRevision tag on the page changed from v3.5.4 to v3.5.5. This indicates a minor system update to the ClinicalTrials.gov page rather than changes to the study details.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing the previous Revision: v3.5.3, indicating a minor platform update to the page without changing its content.SummaryDifference0.0%

- Check40 days agoChange DetectedAdds a citation to NCCN Guidelines: Thyroid Carcinoma, Version 1.2025 (J Natl Compr Canc Netw. 2025). This reference provides guideline context for thyroid cancer management without altering the study’s core content.SummaryDifference0.0%

- Check47 days agoChange DetectedA new final ARROW study article on pralsetinib in RET-altered solid tumors was added to Publications (J Clin Oncol, May 2026) with DOI 10.1200/JCO-25-01489. The previous online-ahead-of-print citation for this article was removed.SummaryDifference0.0%

- Check55 days agoChange DetectedThe page’s displayed revision/version in the footer was updated from v3.5.2 to v3.5.3, indicating a technical update to the site interface rather than a change to the trial record.SummaryDifference0.0%

Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.